I hear what you're saying Mer.
I think that the whole investing community has lost sight of the plusses:
1/ The drug does something, they don't know exactly what, yet. There have been 'observed' improvements by physicians.
2/ The company has a 'raft' of other products under review.
Especially PBT434 (parkinsons), and PBT513 (glioblastome) from which a really good friend of mine recently died.
3/ The price is down to 'almost cash-value'.
For the sake of everyone I hope for a turn-around in attitude in the near future.
Regards K
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.001(4.17%) |
Mkt cap ! $114.0M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.2¢ | $163.0K | 13.45M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 2326338 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 6019089 | 20 |
View Market Depth
| Last trade - 15.02pm 15/07/2025 (20 minute delay) ? |
| ATH (ASX) Chart |